The presented facts suggest that import testing does not protect patients. On the contrary, it introduces potential risks to access of medicines and reduces the remaining shelf life time of medicines driving possible drug shortage. In the absence of data proving the evidence that import testing is decreasing risk to patients, if manufacturers comply with the evolving Good Manufacturing Practices (GMPs) and Good Distribution Practices (GDPs)
regulations, including secure supply chains with documented controls, import testing should be waived. In these cases, importing country's Health Authorities should be confident the product is safe, of high quality, and in compliance with registered specifications.
This article presents risk assessments demonstrating that product quality is continuously controlled. Moreover, import testing does not detect counterfeit or substandard products nor reduces the additional risks related to local distribution channels, as testing occurs at the point of entry into a country.
European Commission, Approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products, EU Council Directive, 75/319/EEC, 20 May 1975.
European Commission, Prevention of the entry into the legal supply chain of falsified medicinal products, EC of the European Parliament and of the council directive, 2011/62/EU, 8 June 2011; amending Directive 2001/83/EC on the Community code relating to Medicinal products for human use.
8.
International Conference on Harmonisation, Pharmaceutical Quality Systems, ICH Q10, 05 June 2008.
9.
International Conference on Harmonisation, Quality Risk Management, ICH Q9, 09 November 2005.
10.
European Federation of Pharmaceutical Industry and Association (EFPIA), Annual inspection survey, please contact EFPIA, www.efpia.eu.
European Commission, Community code relating to medicinal products for human use, EC of the European Parliament and of the council, directive 2001/83/EC, 6 November 2001.
13.
European Commission, Community code relating to medicinal products for human use, EC of the European Parliament and of the council, directive 2001/83/EC, 06 November 2001.
14.
European Commission, Principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use, directive 2003/94/EC, 08 October 2003.
15.
European Commission, Certification by a Qualified Person and Batch Release, EUDRALEX Vol. 4 (EU-GMPs), Annex 16, Ref. Ares (2015) 4234460-12/10/2015, 12. October 2015, 1-12.
16.
European Commission, Importers of medicinal products, EUDRALEX Vol. 4 (EU-GMPs), Concept Paper Annex 21, EMA/238299/2015, 13. May 2015, 1-4.
17.
European Commission, Quality of medicines and Good Manufacturing Practices (GMP), see applied waivers for the ‘written procedure’ at ‘Status of current and past applications', http://ec.europa.eu/health/human-use/quality/index_en.htm.
RamnarineE., JornitzM., LongM.A., O'DonnellK., RönningerS., SmalleyC. and VintherA., Risk based approach for prevention and management of drug shortages, PDA Technical Report68 (2014), 1-45.
